Kelide Lusutrombopag Tablets

1. Indications and Usage
Thrombocytopenia in Chronic Liver Disease: Indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled for surgery.
Goal: To reduce the need for platelet transfusion prior to and following the surgical procedure.
2. Dosage and Administration
Standard Dose: The usual dosage is 1 mg once daily, taken orally.
Duration: Treatment should continue for up to 7 days.
Administration: Can be taken with or without food.
Discontinuation: Treatment should be discontinued once the platelet count reaches the target level or after 7 days, whichever comes first. Avoid long-term use due to the risk of thrombosis.
3. Mechanism of Action
Thrombopoietin Receptor Agonism: Lusutrombopag is a selective agonist of the human thrombopoietin receptor (c-Mpl).
Megakaryocyte Proliferation: By binding to and activating the receptor, it stimulates the proliferation and differentiation of megakaryocytes in the bone marrow, leading to an increase in platelet production.
4. Safety and Warnings
Thromboembolic Events: The most significant risk is the development of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, hepatic vein thrombosis).
Hepatic Function Exacerbation: Can cause exacerbation of hepatic function or hepatic failure, particularly in patients with decompensated liver disease.
Bone Marrow Fibrosis: Long-term use may lead to reticulin or collagen fibrosis in the bone marrow.
Contraindications: Contraindicated in patients with myelodysplastic syndrome or acute myeloid leukemia.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: Thromboembolic events, hepatic function exacerbation, headache, and fatigue.
Serious Adverse Reactions: Hepatic failure, portal vein thrombosis, and bone marrow fibrosis.
Clinical Findings: Clinical trials have demonstrated that lusutrombopag effectively increases platelet counts, reducing the need for preoperative platelet transfusions in patients with chronic liver disease.
6. Drug Interactions
P-Gp Inhibitors: Concomitant use with strong P-glycoprotein (P-gp) inhibitors (e.g., ketoconazole) may increase lusutrombopag exposure.
P-Gp Inducers: Concomitant use with strong P-gp inducers (e.g., rifampin) may decrease lusutrombopag exposure.
Other Drugs: Caution is advised when combining with other drugs that may affect hepatic function or coagulation.
7. Pharmaceutical Information
Active Ingredient: Lusutrombopag.
Strengths: Typically available as 0.5 mg and 1 mg tablets.
Appearance: White to off-white film-coated tablets.
Storage: Store at 25°C (77°F), with excursions permitted to 15°C–30°C (59°F–86°F). Protect from moisture.